[1] |
张良龙, 安宏伟, 赵立智, 等. LncRNA LINC00152过表达在替莫唑胺诱导脑胶质瘤干细胞周期阻滞中的作用机制探讨[J]. 中国癌症杂志, 2020, 30(5): 328-334.
|
|
ZHANG L L, AN H W, ZHAO L Z, et al. Mechanism of overexpression of lncRNA LINC00152 in temozolomide-induced stem cell cycle arrest in glioma[J]. China Oncol, 2020, 30(5): 328-334.
|
[2] |
CHAVDA V, PATEL V, YADAV D, et al. Therapeutics and research related to glioblastoma: advancements and future targets[J]. Curr Drug Metab, 2020, 21(3): 186-198.
doi: 10.2174/1389200221666200408083950
|
[3] |
董明皓, 张霓, 何锋. N6-腺苷酸甲基化修饰在肿瘤发生发展中的作用[J]. 中华实验外科杂志, 2020, 37(9): 1770-1774.
|
|
DONG M H, ZHANG N, HE F. The role of N6-methyladenosine modification in tumorigenesis and development[J]. Chin J Exp Surg, 2020, 37(9): 1770-1774.
|
[4] |
ZHANG C Z, HUANG S Z, ZHUANG H K, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation[J]. Oncogene, 2020, 39(23): 4507-4518.
doi: 10.1038/s41388-020-1303-7
|
[5] |
RUPP C, SCHERZER M, RUDISCH A, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction[J]. Oncogene, 2015, 34(7): 815-825.
doi: 10.1038/onc.2014.18
|
[6] |
PEN A, DUROCHER Y, SLINN J, et al. Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines[J]. Cancer Biol Ther, 2011, 12(7): 634-646.
doi: 10.4161/cbt.12.7.17171
|
[7] |
CUI Q, SHI H L, YE P, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells[J]. Cell Rep, 2017, 18(11): 2622-2634.
doi: 10.1016/j.celrep.2017.02.059
|
[8] |
DU J Y, HOU K Y, MI S, et al. Malignant evaluation and clinical prognostic values of m6A RNA methylation regulators in glioblastoma[J]. Front Oncol, 2020, 10: 208.
doi: 10.3389/fonc.2020.00208
|
[9] |
FANG R P, CHEN X, ZHANG S C, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma[J]. Nat Commun, 2021, 12(1): 177.
doi: 10.1038/s41467-020-20379-7
|
[10] |
LI J F, XIE H Y, YING Y F, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer[J]. Mol Cancer, 2020, 19(1): 152.
doi: 10.1186/s12943-020-01267-6
|
[11] |
HONG L, PU X W, GAN H L, et al. YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A[J]. J Cancer, 2021, 12(13): 3809-3818.
doi: 10.7150/jca.54527
|
[12] |
LI Y F, XI Y F, ZHU G Q, et al. Downregulated IGFBP7 facilitates liver metastasis by modulating epithelial-mesenchymal transition in colon cancer[J]. Oncol Rep, 2019, 42(5): 1935-1945.
|
[13] |
ZHAO Q Y, ZHAO R L, SONG C H, et al. Increased IGFBP7 expression correlates with poor prognosis and immune infiltration in gastric cancer[J]. J Cancer, 2021, 12(5): 1343-1355.
doi: 10.7150/jca.50370
|
[14] |
AKIEL M, GUO C Q, LI X, et al. IGFBP7 deletion promotes hepatocellular carcinoma[J]. Cancer Res, 2017, 77(15): 4014-4025.
doi: 10.1158/0008-5472.CAN-16-2885
|
[15] |
TIAN X Y, ZHANG L, SUN L G, et al. Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma[J]. J Int Med Res, 2014, 42(3): 651-658.
doi: 10.1177/0300060513503926
|
[16] |
ZHANG C, ZHANG M Q, GE S, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K/AKT signaling in gastric cancer[J]. Cancer Med, 2019, 8(10): 4766-4781.
doi: 10.1002/cam4.v8.10
|
[17] |
YANG J B, DING W L, WANG X Y, et al. Knockdown of DNA polymerase ζ relieved the chemoresistance of glioma via inhibiting the PI3K/AKT signaling pathway[J]. Bioengineered, 2021, 12(1): 3924-3933.
doi: 10.1080/21655979.2021.1944027
|
[18] |
EVDOKIMOVA V, TOGNON C E, BENATAR T, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors[J]. Sci Signal, 2012, 5(255): ra92.
|
[19] |
ZHANG L, LIAN R, ZHAO J J, et al. IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma[J]. Cell Biosci, 2019, 9: 44.
doi: 10.1186/s13578-019-0310-2
|
[20] |
HADDADI N, LIN Y G, TRAVIS G, et al. PTEN/PTENP1: ‘regulating the regulator of RTK-dependent PI3K/AKT signalling’, new targets for cancer therapy[J]. Mol Cancer, 2018, 17(1): 37.
doi: 10.1186/s12943-018-0803-3
|